Trial Profile
A phase II non-randomised, open-label, single-arm study to assess the efficacy, safety and tolerability of Nexavar (Sorafenib) monotherapy as third line therapy in patients with progressed ovarian epithelial or primary peritoneal cancer.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Nov 2012
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms OCCASIONE
- 27 Jul 2011 New trial record